• OTS
  • January 31, 2018
SHARE
Post Views: 634

Wada F, Yamamoto T, Ueda T, Sawamura M, Wada S, Harada-Shiba M, Obika S.
Nucleic Acid Ther. 2018 Feb;28(1):50-57.

PubMed

Related articles

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

April 23rd, 2021
Non-specific interactions of antibody-oligonucleotide conjugates with living cells

Non-specific interactions of antibody-oligonucleotide conjugates with living cells

April 23rd, 2021
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

April 23rd, 2021
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

April 23rd, 2021
siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs

siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs

March 15th, 2021